Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Another big Vertex challenger suffers a TKO. And that will cause some problems for the CF champ

3 years ago

HSBC is moving to fill a big gap left by SVB's collapse. And they've recruited some familiar faces for the leap

3 years ago

In a bittersweet transition, Doug Williams takes on his next big biotech challenge

3 years ago

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

3 years ago

Jeffrey Bluestone brings his startup haul to $400M+, joining forces with Regeneron on cell therapies

3 years ago

The venture crew at Mubadala are upping their biotech creation game, taking careful aim at a new frontier in drug development

3 years ago

A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test

3 years ago

Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

3 years ago

John Reed lands in the top R&D post at J&J in his latest Big Pharma debut

3 years ago

The top 100 venture investors in biopharma today. Who's staying at the deals table?

3 years ago

Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role

3 years ago

A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality

3 years ago

Updated: R&D turbulence at Bristol Myers now includes the end of a $650M alliance and the departure of a top research champion

3 years ago

Pioneering biotech icon George Scangos hands in his retirement papers — and this time it’s for real

3 years ago

What’s with Bristol Myers’ R&D job cuts in New Jersey? They’re not saying much

3 years ago

Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster

3 years ago

Updated: Off-the-shelf cell therapy pioneer Allogene recruits a Kite vet to run R&D

3 years ago

Gilead and Arcus want you to believe again in TIGIT. But mixed ARC-7 data are rolling out to a tough crowd

3 years ago

Gossamer’s Faheem Hasnain defends a round of positive PAH data as a clear win. But can these PhII results stand up to scrutiny?

3 years ago

Allogene takes the stage in New York to go deep on its off-the-shelf cell therapies — declaring a first for solid tumors

3 years ago

Amgen may be way late to the obesity game, but the market scouts are loving the blockbuster potential of AMG 133

3 years ago

JP Morgan splashes into the life sciences, tapping Stephen Squinto to run venture team with high-powered advisors

3 years ago

Drew Armstrong is coming to Endpoints(!) And there are some more surprises to come

3 years ago

A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

3 years ago

First page Previous page 1 234 5 6 Next page Last page